XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will ...
H.C. Wainwright maintained a Buy rating on XOMA Ltd . (NASDAQ: NASDAQ:XOMA) but reduced the price target for the company's shares from $123.00 to $104.00. Currently trading at $26.61, the stock sits ...
Analysts have recently evaluated XOMA Royalty and provided 12-month price targets. The average target is $119.2, accompanied ...
XOMA (NASDAQ:XOMA – Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $123.00 to $104.00 in a research note issued to investors on Monday,Benzinga reports.
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the ...
H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...
Short XOMA slightly under 29.28, target 25.85, stop loss @ 29.36 Check the time stamp on this data. Updated AI-Generated ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on XOMA stock, giving a Buy rating on January 7. Discover outperforming stocks and invest smarter with Top Smart Score ...
周一，H.C. Wainwright维持对XOMA Ltd. (NASDAQ: XOMA)的买入评级，但将公司股票的目标价从123.00美元下调至104.00美元。目前，该股交易价格为26.61美元，远低于分析师55美元至123美元的目标区间。目标价的调整归因于该公司将iscalimab从其预测中剔除。尽管如此，该研究公司仍继续对该股票持积极看法。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback